Crossmark

A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with recombinant adeno-associated virus and p38 kinase blockade

Crossref DOI link: https://doi.org/10.1186/s12967-019-02163-4

Published Online: 2019-12-19

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mirandola, Leonardo

Chiriva-Internati, Maurizio

Bresalier, Robert

Piccotti, Lucia

Grizzi, Fabio

Marincola, Francesco M.
License Information

Text and Data Mining valid from 2019-12-01

Version of Record valid from 2019-12-19
More Information

Article History

Received: 1 August 2019

Accepted: 30 November 2019

First Online: 19 December 2019

Ethics approval and consent to participate

: Samples from human patients were obtained from commercially available sources, collected under IRB approved specimen collection protocols and registered sites, with IRB approved informed consent forms and with HIPAA complaint authorization forms, and were received by Kiromic after de-identification.

: Not applicable.

: Maurizio Chiriva-Internati is CEO and founder of Kiromic. Leonardo Mirandola is VP of R&D at Kiromic. Francesco M. Marincola is VP of Translational Research at Kiromic. Lucia Piccotti is a Research Associate at Kiromic. Robert Bresalier and Fabio Grizzi have no competig interests.

Document is current

Any future updates will be listed below